The Sickle Cell Clinical Trials Network: One Year In
The Hematologist Editor-in-Chief, Dr. Laura Michaelis, spoke with Drs. Charles Abrams and Sophie Lanzkron about a groundbreaking ASH initiative started approximate
Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?
Dr. Kahl studies the biologic underpinnings of a new entity that does not meet the classical definition of double-hit (DH) DLBCL but has gene expression signatures and clin
Dr. Osunkwo challenges the belief that normal saline boluses are the best treatment for vaso-occlusive pain in SCD.
Dr. Jacobson reviews a study that looks at PET-adapted strategies for the treatment of advanced-stage Hodgkin lymphoma.
Drs. Donna DiMichele and Keith Hoots of NHLBI talk about grants and resources available to hematologists as well as the importance of talking to program officers during the application process.
July/August 2019Volume 16, Issue 4
View all Features articles
View all Diffusion articles
Dr. Silverstein stresses the important role different people, including staff, volunteers, and board and committee members, play in moving the Society forward and furthering its mission.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology